---

COLINZ LABORATORIES LIMITED
A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2013

					(Rupees in '000')
S. No.	Particulars		Un -audited		Audited
			Quarter Ended		Year Ended
			30.06.2013	31.03.2013	30.06.2012	31.03.2013
PART - I
1	(a) Income from Operation
		Gross Sales	20,712	17,481	23,253	76,818
		Less: Excise Duty	1,398	1,280	1,547	5,282
	Net Sales		19,314	16,201	21,706	71,536
	(b) Other Operating  Income		-	-	-	323
	Total Income from Operation		19,314	16,201	21,706	71,859
2	Expenditure		-	-	-	-
	(a)	Consumption of Materials	6,601	3,152	5,984	21,402
	(b)	Purchase of Goods Traded	1,777	1,144	1,870	5,460
	(c)	(Increase)/Decrease in stock in trade	15	2,434	2,389	1,702
	(d)	Staff Cost	6,212	5,566	6,881	25,748
	(e)	Depreciation	655	659	653	2,619
	(f)	Other Expenditure	3,397	2,556	3,112	12,083
	Total Expenditure		18,657	15,511	20,889	69,014
3	Profit /Loss from Operation Before Other Income (1-2)		657	690	817	2,845
4	Other  Income /(Loss)		51	266	206	775
5	Profit /Loss before Interest & Exceptional items (3+4)		708	956	1,023	3,620
6	Interest		405	467	537	2,021
7	Profit /Loss  after Interest but before exceptional items (5-6)		303	489	486	1,599
8	Exceptional items		-	-	-	-
9	Profit /Loss before Tax (7-8)		303	489	486	1,599
10	Tax Expenses (Provision for Taxation):      Current tax		-	-	-	297
		Deffered tax	-	-	-	504
11	Net Profit/Loss  after Tax (9-10)		303	489	486	798
12	Paid up Equity Share Capital (Face Value 10/- Per Share)		354,35	354,35	354,35	354,35
	[Net of allotment money in arrears]
13	Reserves Excluding Revaluation Reserves		-	-	-	8,428
14	Earning per share (EPS) before extraordinary item (not Annualised)		-	-	-	-
	Basic & Diluted		-	-	-	0.17
PART-II	A. PARTICULARS  OF SHAREHOLDING
1	Public Shareholding
	i)	Number of Shares	29,04,901	29,04,901	29,04,900	29,04,901
	ii)	Percentage of shareholding	63.55%	63.55%	63.55%	63.55%
2	Promoters and promoter group Shareholding
	a)	Pledged/Encumbered
	i)	Number of shares	-	-	-	-
	ii)	Percentage of shares (as a % of the total shareholding of	-	-	-	-
		promoter and promoter group)
	iii)	Percentage of shares (as a% of the total share capital of the company)	-	-	-	-
	b)	Non-encumbered
	i)	Number of Shares	16,66,099	16,66,099	16,66,100	16,66,099
	ii)	Percentage of shares (as a% of the total shareholding)	36.45%	36.45%	36.45%	36.45%
		of promoter and promoter group)
	iii)	Percentage of shares (as a % of the total share capital of the company)	100%	100%	100%	100%

 

	B. INVESTORS COMPLAINTS		3 Months ended 30.06.13
	Pending at Begining of the Quarter		NIL
	Received During the Quarter		NIL
	Disposed of During the Quarter		NIL
	Remaining at the end of the Quarter		NIL

 

NOTES :-

1. The Board of Director's noted that the revenue in this quarter was less compared to the first quarter of 2012-13 due to the Strike of Wholesalers of Medicine, in Maharashtra, in the entire month of June-2013. The above financial results have been taken on record at a meeting of Board of Directors held on  31.07.2013 The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable. Previous period figures have been regrouped wherever required.

 

	For and on behalf of the Board
	COLINZ LABORATORIES LIMITED
Mumbai	Dr. L. S. Mani
31.07.2013	Chairman & Managing Director.

                                                                                                                     

(Top)